Doctors inject chemo directly into lung tumors in early trial
NCT ID NCT04311762
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This early-phase trial tests a new method to deliver the chemotherapy drug cisplatin directly into lung tumors using a bronchoscope. The goal is to find the safest dose and see if this approach can help control stage IV lung cancer. Only 16 participants are enrolled, and the main focus is on safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Vermont
Burlington, Vermont, 05405, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cisplatin
What this could lead to
If successful, this could provide a new way to deliver chemotherapy directly to lung tumors, potentially reducing side effects and improving local control.
What could go wrong
This is a very early phase 1 trial with only 16 participants, focused on safety and dosing. It may not show significant benefit, and there are risks from the procedure and drug toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.